BARDA offers a tiny startup up to $812M to create a US-based drug manufacturer — and the CEO comes with a price gouging controversy on his résumé
BARDA has tapped a largely unknown startup to ramp up production of a list of drugs that may be at risk of running short in the US. And the deal, which comes with up to $812 million in federal funds, was inked by a CEO who found himself in the middle of an ugly price gouging controversy a few years ago.
The feds’ new partner — called Phlow — won a 4-year “base” contract of $354 million, with another $458 million that’s on the table in potential options to sustain the outfit. That would make it one of the largest awards in BARDA’s history.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 87,700+ biopharma pros reading Endpoints daily — and it's free.